A final discussion point is real-world applicability. Although PHAROS presents exceptional PFS, the modest difference between ...
A China-developed KRAS inhibitor led to objective responses in half of patients with previously treated KRAS-mutant non-small cell lung cancer (NSCLC), a prospective non-randomized trial showed.
Hosted on MSN
GSK’s new study on belantamab mafodotin: A potential game-changer for multiple myeloma treatment
GlaxoSmithKline (GSK) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) has announced a new clinical study titled ‘A Phase 2, Multicenter, Open Label, Non-randomized Study to ...
Medical research is essential for advancing the understanding of health, diseases, and treatments. There are many types of studies that serve different purposes. Medical research, or health research, ...
Gilead's ARTISTRY-2 trial shows BIC/LEN is non-inferior to Biktarvy in virologically suppressed adults with HIV, with no new safety signals. ARTISTRY-2's design involved a randomized, double-blind ...
Tarlatamab combined with PD-L1 inhibitors shows potential in improving survival for ES-SCLC, with a median OS of 25.3 months. The combination may bypass tumor immune evasion by redirecting T-cells to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback